免疫检查点阻断通过扩增效应 CD8⁺ T 细胞克隆增强淋巴细胞清除性化疗诱导的抗肿瘤免疫
Immune Checkpoint Blockade Augments Lymphodepleting Chemotherapy-Induced Antitumor Immunity by Expanding Effector CD8+ T-cell Clones.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
程序性死亡受体 1 阳性肿瘤浸润 T 细胞与抗程序性死亡受体 1 抗体偶联提升过继性 T 细胞疗法疗效
英文原题：Coupling programmed cell death 1-positive tumor-infiltrating T cells with anti-programmed cell death 1 antibody improves the efficacy of adoptive T-cell therapy.
查看英文原题
Coupling programmed cell death 1-positive tumor-infiltrating T cells with anti-programmed cell death 1 antibody improves the efficacy of adoptive T-cell therapy.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
研究概要
利用 TIL 疗法联合免疫检查点抗体的策略可能扩展至 ACT 的其他治疗靶点。
研究思路结论见上方概要
背景
过继细胞治疗（ACT）使用TIL（肿瘤浸润淋巴细胞）（TILs）在临床试验中取得了巨大成功。表达程序性细胞死亡1（PD-1）的TILs对自体肿瘤细胞显示出高特异性。然而，由于肿瘤免疫微环境（TIME），观察到的治疗效果有限。
方法
将 PD-1 + 体外扩增的 TIL 与抗 PD-1 单克隆抗体（aPD-1）偶联，可在不改变 TIL 高肿瘤靶向能力的情况下，重新激活 TIL 对实体瘤的抗肿瘤反应。
结果
使用荷黑色素瘤小鼠模型，经aPD-1阻断的PD-1 + TILs（PD-1 + TILs-aPD-1）表现出高度的肿瘤靶向能力以及在TIME中改善的抗肿瘤反应。用PD-1 + TILs-aPD-1治疗的小鼠肿瘤生长显著延迟。
展开英文摘要原文
METHODS
Coupling PD-1 + ex vivo-derived TILs with a monoclonal antibody against anti-PD-1 (aPD-1) reinvigorated the anti-tumor response of TILs against solid tumor without altering their high tumor targeting ability.
RESULTS
Using a melanoma-bearing mouse model, PD-1 + TILs blocked with aPD-1 (PD-1 + TILs-aPD-1) exhibited a high capability for tumor targeting as well as improved anti-tumor response in TIME. Tumor growth was substantially delayed in the mice treated with PD-1 + TILs-aPD-1.
CONCLUSIONS
The strategy utilizing TIL therapy coupled with immune checkpoint antibodies may extend to other therapeutic targets of ACT.
论文信息
- 作者
- Chu J、Wang C、Ma Q、Dai H、Xu J、Ogunnaike EA、Peng F、Shi X
- 第一作者单位
- Institute of Functional Nano & Soft Materials, Jiangsu Key Laboratory for Carbon-Based Functional Materials and Devices, Soochow University, Suzhou, China.China
- 通讯作者单位
- Institute of Functional Nano & Soft Materials, Jiangsu Key Laboratory for Carbon-Based Functional Materials and Devices, Soochow University, Suzhou, China. Electronic address: cwang@suda.edu.cn.China
- 文献类型
- 非美国政府资助研究
- 期刊
- Cytotherapy2022 Mar
- 原文标识
- PubMed 34690063 · DOI 10.1016/j.jcyt.2021.08.004